Neogen Quarterly Cash Flow Statement
NASDAQ: NEOGHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
11.85+0.14 (+1.20%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neogen free cash flow
In the quarter ended Aug 31, 2026, Neogen generated $12.9 million of operating cash flow and spent $8.2 million on capital expenditures. That left free cash flow of $4.7 million, a free-cash-flow margin of 2.1% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Neogen cash flow statement (quarterly)
| Quarter (USD) | Q1 20272026-08-31 | Q4 20262026-05-31 | Q3 20262026-02-28 | Q2 20262025-11-30 | Q1 20262025-08-31 | Q4 20252025-05-31 | Q3 20252025-02-28 | Q2 20252024-11-30 | Q1 20242024-08-31 | Q4 20242024-05-31 | Q3 20242024-02-29 | Q2 20242023-11-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -11.90M | -11.30M | -17.00M | -15.90M | 36.30M | -612.20M | -10.90M | -456.30M | -12.60M | -5.39M | -2.02M | -3.49M |
| Net Income growth (YoY) | -132.78% | — | — | — | — | — | — | — | -938.32% | -196.81% | -124.69% | — |
| Depreciation & Amortization | 29.10M | 29.40M | 28.92M | 28.88M | 29.10M | 30.30M | 29.35M | 30.05M | 29.80M | 28.85M | 29.65M | 29.47M |
| Stock-Based Compensation | 3.10M | 3.00M | 1.10M | 4.30M | 5.00M | 4.30M | 4.20M | 4.82M | 3.98M | 3.97M | 3.68M | 3.51M |
| Change in Working Capital | 7.10M | 9.50M | 20.12M | -2.52M | 31.00M | 10.00M | 10.18M | -3.82M | -22.76M | 17.48M | -51.34M | -19.23M |
| Operating Cash Flow | 12.90M | 30.20M | 22.70M | 19.50M | 10.80M | 16.40M | 19.46M | 40.25M | -17.91M | 26.78M | -30.21M | 15.71M |
| Capital Expenditures | -8.20M | -4.00M | -11.63M | -11.67M | -24.00M | -16.10M | -32.91M | -17.16M | -38.43M | -24.23M | -32.12M | -24.42M |
| Investing Cash Flow | -8.20M | -4.00M | -11.56M | -11.64M | 97.70M | -15.90M | -32.48M | -17.16M | -33.66M | -17.51M | -14.64M | 11.54M |
| Debt Repaid | -20.00M | 0 | 0 | 0 | -100.00M | -550.00M | 0 | 98.00K | -98.00K | 0 | 0 | — |
| Financing Cash Flow | -19.00M | -300.00K | 744.00K | -444.00K | -99.40M | -2.10M | 930.00K | -1.41M | 979.00K | -99.00K | 1.25M | -310.00K |
| Net Change in Cash | -13.50M | 25.60M | 14.56M | 6.54M | 9.80M | 1.30M | -12.52M | 19.75M | -50.13M | 9.20M | -44.33M | 26.93M |
| Free Cash Flow | 4.70M | 26.20M | 11.07M | 7.83M | -13.20M | 300.00K | -13.45M | 23.10M | -56.35M | 2.55M | -62.33M | -8.70M |
This table shows 12 quarterly periods of Neogen's cash flow statement, from Q1 2027 back to Q2 2024, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NEOG's reporting calendar. What is a cash flow statement?